Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease

Brain

Volumn 138, Issue 1, 2015, Pages 203-216

  Cantarella, Giuseppina ^a   Di Benedetto, Giulia ^a,b   Puzzo, Daniela ^a   Privitera, Lucia ^a   Loreto, Carla ^a   Saccone, Salvatore ^a   Giunta, Salvatore ^a   Palmeri, Agostino ^a   Bernardini, Renato ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CYTOKINE ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; TAU PROTEIN; TNFSF10 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; HIPPOCAMPUS; IN VIVO STUDY; MALE; MORRIS WATER MAZE TEST; MOUSE; NEUROTOXICITY; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; ANIMAL; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLIOSIS; HUMAN; IMMUNOLOGY; MAZE TEST; MEMORY; METABOLISM; MUTATION; RECOGNITION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES, MONOCLONAL; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLIOSIS; HIPPOCAMPUS; HUMANS; MALE; MAZE LEARNING; MEMORY; MICE; MICE, TRANSGENIC; MUTATION; PRESENILIN-1; RECOGNITION (PSYCHOLOGY); TAU PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84925229148     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu318     Document Type: Article

References (50)

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-21.
2. Almasan A, Ashkenazi A. Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003; 14: 337-48.
3. Amor S, Peferoen LAN, Vogel DYS, Breur M, Valk P, van der, Baker D, et al. Inflammation in neurodegenerative diseases-an update. Immunology 2014; 142: 151-66.
4. Avila-Muñoz E, Arias C. When astrocytes become harmful: Functional and inflammatory responses that contribute to Alzheimer's disease. Ageing Res Rev 2014; 18C: 29-40.
5. Banks WA. Immunotherapy and neuroimmunology in Alzheimer's disease: A perspective from the blood-brain barrier. Immunotherapy 2010; 2: 1-3.
6. Barker GRI, Warburton EC. When is the hippocampus involved in recognition memory?. J Neurosci 2011; 31: 10721-31.
7. Bettens K, Sleegers K, Broeckhoven C, Van. Genetic insights in Alzheimer's disease. Lancet Neurol 2013; 12: 92-104.
8. Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, Zhu X, et al. Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology 2010; 59: 290-4.
9. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
10. Broadbent NJ, Gaskin S, Squire LR, Clark RE. Object recognition memory and the rodent hippocampus. Learn Mem Cold Spring Harb N 2010; 17: 5-11.
11. Broussard GJ, Mytar J, Li R, Klapstein GJ. The role of inflammatory processes in Alzheimer's disease. Inflammopharmacology 2012; 20: 109-26.
12. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments. J Biol Chem 2010; 285: 13107-20.
13. Cantarella G, Benedetto Di, Scollo M, Paterniti I, Cuzzocrea S, Bosco P, et al. Neutralization of tumor necrosis factor-related apoptosis-inducing ligand reduces spinal cord injury damage in mice. Neuropsychopharmacol 2010; 35: 1302-14.
14. Cantarella G, Lempereur L, D'Alcamo MA, Risuglia N, Cardile V, Pennisi G, et al. Trail interacts redundantly with nitric oxide in rat astrocytes: Potential contribution to neurodegenerative processes. J Neuroimmunol 2007; 182: 41-7.
15. Cantarella G, Uberti D, Carsana T, Lombardo G, Bernardini R, Memo M. Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity. Cell Death Differ 2003; 10: 134-41.
16. Chakraborty S, Kaushik DK, Gupta M, Basu A. Inflammasome signaling at the heart of central nervous system pathology. J Neurosci Res 2010; 88: 1615-31.
17. Clausen BH, Lambertsen KL, Babcock AA, Holm TH, Dagnaes-Hansen F, Finsen B. Interleukin-1beta and tumor necrosis factoralpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J Neuroinflammation 2008; 5: 46.
18. Deverman BE, Patterson PH. Cytokines and CNS development. Neuron 2009; 64: 61-78.
19. Genc S, Egrilmez MY, Yaka E, Cavdar Z, Iyilikci L, Yener G, et al. TNF-related apoptosis-inducing ligand level in Alzheimer's disease. Neurol Sci 2009; 30: 263-7.
20. Griffin WST. Neuroinflammatory cytokine signaling and Alzheimer's disease. N Engl J Med 2013; 368: 770-1.
21. Griffiths MR, Gasque P, Neal JW. The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol 2009; 68: 217-26.
22. He BP, Wen W, Strong MJ. Activated microglia (BV-2) facilitation of TNF-alpha-mediated motor neuron death in vitro. J Neuroimmunol 2002; 128: 31-8.
23. Heinzl S. TOR inhibitors for immunosuppression [in German]. Med Monatsschrift Für Pharm 2000; 23: 246-51.
24. Huang Y, Erdmann N, Peng H, Zhao Y, Zheng J. The role of TNF related apoptosis-inducing ligand in neurodegenerative diseases. Cell Mol Immunol 2005; 2: 113-22.
25. Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004; 45: 583-95.
26. Kraft AW, Hu X, Yoon H, Yan P, Xiao Q, Wang Y, et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J 2013; 27: 187-98.
27. Kamphuis W, Middeldorp J, Kooijman L, Sluijs JA, Kooi E-J, Moeton M, et al. Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer's disease. Neurobiol Aging 2014; 35: 492-510.
28. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.
29. Loewith R, Hall MN. Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics 2011; 189: 1177-201.
30. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, et al. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 2008; 1207: 225-36.
31. Mould DR, Sweeney KRD. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007; 10: 84-96.
32. Nagele RG, D'Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res 2003; 971: 197-209.
33. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-21.
34. Palmeri A, Privitera L, Giunta S, Loreto C, Puzzo D. Inhibition of phosphodiesterase-5 rescues age-related impairment of synaptic plasticity and memory. Behav Brain Res 2013; 240: 11-20.
35. Patel BB, Holland NW. Mild cognitive impairment: Hope for stability, plan for progression. Cleve Clin J Med 2012; 79: 857-64.
36. Puzzo D, Bizzoca A, Privitera L, Furnari D, Giunta S, Girolamo F, et al. F3/Contactin promotes hippocampal neurogenesis, synaptic plasticity, and memory in adult mice. Hippocampus 2013; 23: 1367-82.
37. Puzzo D, Privitera L, Palmeri A. Hormetic effect of amyloid-b peptide in synaptic plasticity and memory. Neurobiol Aging 2012; 33: 1484.e15-24.
38. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-44.
39. Rafii MS. Update on Alzheimer's disease therapeutics. Rev Recent Clin Trials 2013; 8: 110-8.
40. Rosenmann H. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2013; 10: 217-28.
41. Schenk F, Morris RG. Dissociation between components of spatial memory in rats after recovery from the effects of retrohippocampal lesions. Exp Brain Res 1985; 58: 11-28.
42. Selkoe DJ. The origins of Alzheimer disease: A is for amyloid. JAMA 2000; 283: 1615-7.
43. Shaftel SS, Kyrkanides S, Olschowka JA, Miller JH, Johnson RE, O'Banion MK. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 2007; 117: 1595-604.
44. Uberti D, Cantarella G, Facchetti F, Cafici A, Grasso G, Bernardini R, et al. TRAIL is expressed in the brain cells of Alzheimer's disease patients. Neuroreport 2004; 15: 579-81.
45. Veeraraghavalu K, Zhang C, Zhang X, Tanzi RE, Sisodia SS. Agedependent, non-cell-autonomous deposition of amyloid from synthesis of b-amyloid by cells other than excitatory neurons. J Neurosci 2014; 34: 3668-73.
46. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006; 6: 404-16.
47. Willard LB, Hauss-Wegrzyniak B, Danysz W, Wenk GL. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp Brain Res 2000; 134: 58-65.
48. Wong M. Mammalian target of rapamycin (mTOR) pathways in neurological diseases. Biomed J 2013; 36: 40-50.
49. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease - A double-edged sword. Neuron 2002; 35: 419-32.
50. Zhou M, Wang CM, Yang WL, Wang P. Microglial CD14 activated by NOS2 contributes to neuroinflammation in cerebral ischemia. Brain Res 2013; 1506: 105-14.